United States: The Inversion Craze: Will Today's Routine Tax Planning Be Retroactively Outlawed?

Alongside the more typical summer fare, such as coverage of the best beach reading and the latest action movie blockbuster, this summer the media have been abuzz with seemingly daily reports on the latest so-called "inversion" transactions shifting a U.S.-based multinational corporation's tax residence offshore. Recently announced transactions include the Medtronic acquisition of Irish-listed Covidien (which itself had previously inverted); Mylan's acquisition of the Abbott Laboratories non-U.S. specialty and branded generics businesses for $5.3 billion in stock; and AbbVie's $54 billion acquisition of Shire, a London-listed, Jersey incorporated, Irish tax resident corporation. Other transactions remain in the planning stages (Walgreens-Boots), and the largest such transaction proposed to date (Pfizer's $100 billion-plus bid for UK-based AstraZeneca) has been shelved, at least temporarily, but remains very much in the media and political spotlight.

The pace at which inversion transactions are being announced shows no sign of slowing, and could even accelerate further if companies begin to make use of a variant which has been referred to as a "spinversion."1 A spinversion would allow a larger conglomerate to spin-off one line of business to its shareholders using a separate entity that would then move offshore via a merger with a non-U.S. partner. Because this type of transaction would involve only one business line rather than the whole company, it could make inversion a possibility for companies for which a whole-company transaction would not be commercially viable (either because of sheer size or commercial constraints).

All of this activity is occurring notwithstanding recently proposed legislation (discussed below) intended to put a stop to the exodus of U.S. companies to foreign jurisdictions that are considered to be more tax-favorable than the U.S. While these transactions undoubtedly are motivated by strategic and competitive factors, there is no mistaking that tax savings also are a key driver of these deals: The Pfizer-AstraZeneca combination was estimated to reduce taxes by at least $1 billion per year post-closing, and the New York Times described the AbbVie-Shire transaction as "For $53 Billion, Tax Savings."2

Apparently spurred into action by the Pfizer-AstraZeneca proposal, in May Democrats in both houses of Congress introduced legislation that would tighten the existing anti-inversion rules. Significantly, the proposed changes would apply to transactions completed after May 8, 2014, a threat of retroactivity clearly intended (at least) to halt inversion activity immediately and give Congress time to reach a consensus on a longer term legislative solution to the overall inversion problem.

To provide some context to evaluate the new proposal, this alert will first briefly describe how and why inversions have been accomplished in the recent past, then discuss the key proposed changes to the existing rules and the options available to multinationals in the face of considerable legislative uncertainty.


In very simple terms, an inversion involves redomiciling a U.S. corporation into a foreign jurisdiction, so that a multinational group of corporations becomes controlled by a foreign parent rather than a U.S. parent. The revised group structure creates the opportunity to pursue three key tax benefits:

  • First, while a U.S. corporation is taxed on its worldwide income, the inversion generally permits the group to limit future U.S. taxation to U.S. earnings only. This benefit is amplified by the relatively high corporate tax rates in the U.S., particularly when compared to the headline rates in the countries (such as the UK) into which U.S. companies typically invert, and the fact that these countries often have incentive regimes applicable to certain types of income (such as from patents) that may be quite beneficial.
  • Second, while in many cases a U.S. corporation pays U.S. tax upon a repatriation of earnings from its foreign subsidiaries or the use of those earnings to acquire U.S. assets, the new foreign parent generally will be able to use the group's future non-U.S. earnings to acquire U.S. businesses or to pay dividends to shareholders without paying U.S. tax on those earnings.
  • Third, within limits, following the inversion the group can engage in certain base erosion techniques, such as the payment by the U.S. and other operating companies of deductible royalties or interest to lower-taxed group members.

Legislation has been enacted in varying forms over the past few decades in an effort to stem the tide of corporations exiting the United States. As a result, under current law inversion is not without its U.S. tax costs; most inversion transactions are taxable to U.S. shareholders, and the usual post-inversion restructuring typically results in an additional significant U.S. corporate tax cost. However, the current inversion calculus is that the future tax savings are simply worth the cost. Thus, by all accounts, existing legislation has failed to achieve its goals and corporations continue to find it worthwhile to reorganize so that they are no longer "U.S. multinationals" but merely "multinationals" with substantial U.S. operations, often with their headquarters and significant operations remaining in the United States after they have expatriated.

Historically there were a greater number of ways to achieve this end result, but today for virtually all companies there is only one viable option: to merge with a non-U.S. company in a transaction in which the shareholders of the offshore merger partner receive more than 20% of the shares in the combined offshore entity (which may be the merger partner itself or a third party jurisdiction holding company). Failure to exceed this 20% threshold will result in the combined corporation, although it is organized under foreign corporate law, being treated as a U.S. corporation for U.S. tax purposes. For this reason, virtually all inversion transactions satisfy this greater-than-20% share ownership test.


Many members of Congress have concluded that existing law provides insufficient barriers to corporate migration and that it must be significantly changed. The Obama administration has taken a similar position, most recently and adamantly in the form of a letter this week from Treasury Secretary Jacob Lew to Congressional leaders from both parties. However, there is a lively debate as to whether any change to the anti-inversion regime should be enacted on its own, or only as part of overall corporate (or corporate and individual) tax reform. Legislators in the first camp have introduced bills in both houses of Congress that would tighten the existing rules in two key respects:

  • First, the stock ownership threshold would be reduced, so that treatment of the combined offshore entity as a U.S. corporation for U.S. tax purposes would apply whenever the former shareholders of the U.S. corporation own more than 50% of the foreign entity following the inversion.
  • Second, regardless of the degree of shareholder continuity, U.S. tax residence would continue to apply if, following the transaction, management and control of the group that includes the former U.S. parent occurs primarily in the United States and the group has significant business activities in the United States. For this purpose, "significant U.S. business activities" would be deemed to exist if at least 25% of any of the group's (i) employees (by headcount or compensation), (ii) assets or (iii) income were in the United States. This change would be a radical departure from historic U.S. law that generally has looked solely to place of incorporation in determining tax residency.

The bill as introduced in the Senate would allow the changes to expire after two years, a feature intended to spur Congress to enact comprehensive corporate tax reform within that time frame and thereby also address the inversion issue.


Particularly given the climate in the present Congress, it is difficult to predict with any certainty whether or when the proposals described above (or any other possible relevant legislation) might be enacted and, if ultimately enacted, whether they will apply retroactively as proposed. There appears to be a growing consensus among members of both political parties that legislative action is needed to stem the tide of U.S. corporations exiting the U.S. However, at present there is no agreement on whether inversions are best addressed through punitive measures, such as the pending bills, or through fundamental corporate tax reform that presumably would attempt to induce multinationals to remain in the U.S. through enactment of a more benign international tax regime.

The possibility of the current legislation being enacted does not seem to be having a significant chilling effect on public transactions. None of them has featured the delivery of over 50% of the combined corporation's stock to the shareholders of the non-U.S. merger partner. Therefore, all of the transactions on their face would appear to be taxable under the current proposals, given the retroactive effective date. One could conclude from this that the parties involved may well be of the view that either the legislation will not be passed, or that if it is passed, the current retroactive effective date will not be included. Alternatively, there may be a "nothing ventured, nothing gained" mentality at work here: If the group was U.S. before the transaction, and in the worst case under the proposed legislation will be taxed as U.S. afterward, there may be no compelling reason not to pursue the foreign target through an inversion structure if the acquisition makes good business sense.

U.S. multinationals (particularly in the pharmaceutical and, to a lesser extent, technology industries) continue to seek to expatriate from the United States in order to reduce their current tax burden and to be able to access offshore cash more easily. This is despite the current U.S. tax costs incurred at the shareholder level, on the merger itself, and at the corporate level in connection with the usual post-inversion restructuring of subsidiaries and operations. Anecdotal evidence suggests that despite the upfront costs, the companies involved believe that self-help via inversions will ultimately yield more beneficial results (and certainly quicker results) than those that may eventually come with major tax reform.

Companies in other industries, particularly those with a direct U.S. consumer base or with substantial U.S. government contracts or with rights to receive reimbursements from the U.S. government for various types of payments, may find an inversion much more difficult to accomplish.3 For example, it has been suggested that these considerations may be viewed as significant impediments to an offshore move in the Walgreens-Boots merger, although expatriation continues to be explored in that transaction given the significant tax savings that would be expected to be achieved.


Any company contemplating a move offshore will need to vigorously examine the pros and cons involved, including the possibility that adverse legislation could be passed with a retroactive effective date. Furthermore, the costs that already exist under present law are not insignificant and must be factored into the overall calculus. Last, and certainly not least, the ability to expatriate depends upon finding a suitable merger partner and the ability to deliver more than 20% of the shares in the combined entity to the merger partner's shareholders.

Amidst all of the current buzz about inversion transactions, it is important to bear in mind that these are significant, and in many cases very substantial, third party business combinations featuring all of the hurdles that typically accompany such a global union: Challenging negotiations regarding the future management, direction and geographical presence of the combined entity; the need for regulatory approvals from the various countries involved, each of which might have its own, potentially adverse, interest in where and how the combined business operates; and, not least, the challenge of successfully integrating the two businesses following the transaction. Within the past six months, at least one announced inversion transaction (Omnicom-Publicis) collapsed, apparently under the weight of these considerations, and at least one other (Pfizer-AstraZeneca) seemed unable to gain traction for similar reasons. Given these commercial realities and the possibility that the intended tax savings could be limited or eliminated by the effect of retroactive or even prospective legislation, in the current climate a potential inversion transaction should only be pursued if the strategic and other non-tax reasons for the combination are sufficiently compelling to justify the combination even in the absence of the anticipated tax savings.


1 For recent coverage of "spinversions," see Brooke Sutherland, "Conglomerates Could Escape U.S. Taxes Through 'Spinversions'", Bloomberg BNA Daily Tax Report at 134 DTR G-4 (July 10, 2014).

2 New York Times, July 18, 2014, p. A1

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions